Investment Rating - The report does not explicitly state an investment rating for the hand-foot-mouth disease vaccine industry Core Insights - The hand-foot-mouth disease vaccine market in China has shown fluctuating growth rates, with a significant decline projected for the coming years. The market size in 2023 is estimated at 16.76 billion RMB, down from 26.41 billion RMB in 2022, reflecting a decrease of 36.53% [17] - The average price of the vaccines has remained stable at 180 RMB per dose from 2017 to 2027, indicating no significant price changes in recent years [32][33] Market Size Overview - The market size (in billion RMB) from 2017 to 2027 is as follows: - 2017: 23.45 - 2018: 52.01 - 2019: 33.93 - 2020: 27.93 - 2021: 35.46 - 2022: 26.41 - 2023E: 16.76 - 2024E: 13.83 - 2025E: 12.17 - 2026E: 10.95 - 2027E: 9.86 - The growth rates for these years show significant volatility, with the highest growth of 121.81% in 2018 and a projected decline of 36.53% in 2023 [17] Vaccine Approval Quantity - The number of approved doses for the enterovirus 71 inactivated vaccine from 2017 to 2027 is as follows (in ten thousand doses): - 2017: 1,302.76 - 2018: 2,889.66 - 2019: 1,884.85 - 2020: 1,551.64 - 2021: 1,969.89 - 2022: 1,467.21 - 2023E: 931.18 - 2024E: 768.13 - 2025E: 675.96 - 2026E: 608.36 - 2027E: 547.53 - The growth rates for these years also reflect significant fluctuations, with a peak growth of 121.81% in 2018 and a projected decline of 36.53% in 2023 [30] Average Vaccine Price - The average bidding price for the vaccines has remained constant at 180 RMB per dose from 2017 to 2027, indicating stability in pricing despite market fluctuations [32][33]
中国手足口病疫苗行业市场规模测算逻辑模型 头豹词条报告系列
Tou Bao Yan Jiu Yuan·2024-05-23 12:00